Skip to main
VERU

Veru (VERU) Stock Forecast & Price Target

Veru (VERU) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Veru Inc. is positioned favorably within the biopharmaceutical industry, particularly given the expanding market for obesity treatments, as indicated by the significant growth in global spending on obesity medications, which surged from ~$3 billion in 2020 to over $30 billion by 2024. Additionally, the company's focus on developing therapies that address unmet needs in muscle preservation aligns with emerging market trends, including positive outcomes from GLP-1RA clinical trials, which have spurred increased interest and investment in this therapeutic area. Furthermore, the robust sales performance of competitors like Zepbound, which achieved a remarkable 185% year-over-year revenue growth, highlights the substantial opportunity for Veru to capture market share as the demand for innovative treatments continues to escalate in both the oncology and metabolic disease segments.

Bears say

Veru Inc. faces significant risks associated with the uncertainty of its drug development programs, which may hinder future revenue growth and negatively affect stock performance. The company's late-stage drugs are subject to intense competition and higher FDA expectations for efficacy and safety, potentially leading to lower-than-expected revenues. Additionally, turnover among key leaders in regulatory roles, such as the CEO and CMO, may further exacerbate challenges, impacting investor confidence and shares negatively.

Veru (VERU) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Veru and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Veru (VERU) Forecast

Analysts have given Veru (VERU) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Veru (VERU) has a Strong Buy consensus rating as of Dec 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Veru (VERU)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.